A fierce price war has erupted among Indian pharmaceutical companies after the Semaglutide patent expiry, with generics priced up to 90 percent cheaper. The sharp price cuts could expand diabetes and obesity treatment access for millions of patients in India.
As affordable generic weight-loss drugs enter the Indian market, CDSCO has warned against self-medication and misleading advertisements. Regulators stress medical supervision, highlighting potential health risks and enforcing stricter rules for pharmaceutical companies launching these drugs.
Novo Nordisk has launched its once-weekly diabetes and weight-management drug Ozempic in India. The semaglutide-based GLP-1 agonist improves glycaemic control, supports weight loss and may reduce cardiovascular and kidney risks. Prices start at Rs 8,800 per month for the lowest dose
Novo Nordisk has launched Ozempic, its once-weekly semaglutide injection, in India with prices starting at Rs 8,800. Approved for adults with uncontrolled type-2 diabetes, the drug aids glycaemic control, weight management and reduces cardiovascular and kidney risks.
The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories and OneSource Speciality Pharma. Novo Nordisk’s blockbuster weight-loss drug Ozempic Wegovy is expected to be launched soon in India
While each of us should aim to be fit as a fiddle, how we achieve our fitness goals is the real question. With Ozempic and Wegovy becoming a global rage, here's what experts have to say about using semaglutides for weight loss
